Peptipedia
ImmuneFDA ApprovedFDA Approved

Enfuvirtide

Also known as Fuzeon, T-20

A 36-amino acid peptide functioning as an HIV fusion inhibitor that prevents viral entry into cells. The first approved drug in its class.

FDA Approved - HIV salvage therapy
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

90 mg subcutaneous twice daily

Frequency

Twice daily

Duration

Ongoing as part of HIV regimen

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 90 mg subcutaneous twice daily via Subcutaneous injection, Twice daily. Dose range: 90 mg per dose. Duration: Ongoing as part of HIV regimen.

Timing & Administration

Administer via Subcutaneous injection. Frequency: Twice daily.

Mechanism of Action

Binds to HIV gp41, preventing the conformational change needed for virus-cell membrane fusion.

Research Summary

Evidence level: fda approved. Clinical status: FDA Approved - HIV salvage therapy.

Side Effects & Safety

Important Warnings

  • Reserved for salvage therapy due to twice-daily injection requirement and injection site reactions
Injection site reactions (98%)
diarrhea
nausea
fatigue
pneumonia (higher incidence)
hypersensitivity reactions

References

No references available.

Related Peptides

Browse all →
LL-37Immune

A naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.

View profile
Thymosin Alpha-1Immune

A naturally occurring thymic peptide that enhances immune function.

View profile
KPVImmune

A tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH). Known for potent anti-inflammatory effects, particularly in the gut.

View profile